

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Pancrelipase Formulation

Version 1.9      Revision Date: 06.04.2024      SDS Number: 5325641-00010      Date of last issue: 30.09.2023  
Date of first issue: 22.11.2019

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Pancrelipase Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.  
30 Hudson Street, 33rd floor  
07302 Jersey City, New Jersey, U.S.A

Telephone : +1-551-430-6000

E-mail address of person responsible for the SDS : EHSSTEWARD@organon.com

#### 1.4 Emergency telephone number

+1-215-631-6999

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

|                                       |  |
|---------------------------------------|--|
| Skin irritation, Category 2           | H315: Causes skin irritation.  |
| Eye irritation, Category 2            | H319: Causes serious eye irritation.   |
| Respiratory sensitisation, Category 1 | H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled. |

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.  
H319 Causes serious eye irritation.

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

Version 1.9      Revision Date: 06.04.2024      SDS Number: 5325641-00010      Date of last issue: 30.09.2023  
Date of first issue: 22.11.2019

H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements :

### Prevention:

P264 Wash skin thoroughly after handling.  
P280 Wear protective gloves/ eye protection/ face protection.

### Response:

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P332 + P313 If skin irritation occurs: Get medical advice/ attention.  
P337 + P313 If eye irritation persists: Get medical advice/ attention.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

Hazardous components which must be listed on the label:

Pancrelipase

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

May form combustible dust concentrations in air.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

| Chemical name | CAS-No.<br>EC-No.<br>Index-No.<br>Registration number | Classification  | Concentration<br>(% w/w) |
|---------------|---|---|--------------------------|
| Pancrelipase  | 53608-75-6<br>258-659-7                               | Skin Irrit. 2; H315<br>Eye Irrit. 2; H319<br>Resp. Sens. 1;<br>H334 | >= 50 - < 70             |

For explanation of abbreviations see section 16.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Risks : Causes skin irritation.  
Causes serious eye irritation.  
May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : High volume water jet

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Do not use a solid water stream as it may scatter and spread fire.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Sulphur oxides  
Metal oxides

#### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing. Avoid breathing dust, fume, gas, mist, vapours or spray. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Pancrelipase Formulation

Version 1.9      Revision Date: 06.04.2024      SDS Number: 5325641-00010      Date of last issue: 30.09.2023  
Date of first issue: 22.11.2019

place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

| Components   | CAS-No.    | Value type (Form of exposure) | Control parameters                                 | Basis    |
|--------------|------------|-------------------------------|--|----------|
| Pancrelipase | 53608-75-6 | TWA                           | OEB 3 ( $\geq 10 < 100$ $\mu\text{g}/\text{m}^3$ ) | Internal |

#### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

| Substance name    | End Use   | Exposure routes | Potential health effects   | Value                  |
|-------------------|-----------|-----------------|----------------------------|------------------------|
| Calcium carbonate | Workers   | Inhalation      | Long-term systemic effects | 6,36 mg/m <sup>3</sup> |
|                   | Consumers | Ingestion       | Acute systemic effects     | 6,1 mg/kg bw/day       |
|                   | Consumers | Inhalation      | Long-term systemic effects | 1,06 mg/m <sup>3</sup> |
|                   | Consumers | Ingestion       | Long-term systemic effects | 6,1 mg/kg bw/day       |

#### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

| Substance name    | Environmental Compartment | Value    |
|-------------------|---------------------------|----------|
| Calcium carbonate | Sewage treatment plant    | 100 mg/l |

### 8.2 Exposure controls

#### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

|                          |   |  |
|--------------------------|---|--|
| Eye/face protection      | : | Wear safety glasses with side shields or goggles.<br>If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.<br>Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. |
| Hand protection          | : |  |
| Material                 | : | Chemical-resistant gloves  |
| Remarks                  | : | Consider double gloving.   |
| Skin and body protection | : | Work uniform or laboratory coat.<br>Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.<br>Use appropriate degowning techniques to remove potentially contaminated clothing.                    |
| Respiratory protection   | : | If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.<br>Equipment should conform to NS EN 143  |
| Filter type              | : | Particulates type (P)  |

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

|  |   |  |
|--|---|--|
| Physical state                                   | : | solid  |
| Colour   | : | No data available                                |
| Odour  | : | No data available                                |
| Odour Threshold                                  | : | No data available                                |
| Melting point/freezing point                     | : | No data available                                |
| Initial boiling point and boiling range          | : | No data available                                |
| Flammability (solid, gas)                        | : | May form combustible dust concentrations in air. |
| Flammability (liquids)                           | : | Not applicable                                   |
| Upper explosion limit / Upper flammability limit | : | No data available                                |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

Lower explosion limit / Lower flammability limit : No data available

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics  
Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

Hazardous reactions : May form combustible dust concentrations in air.  
Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Pancrelipase:

Acute oral toxicity : LD50 (Rat): > 10.000 mg/kg

#### Skin corrosion/irritation

Causes skin irritation.

#### Components:

##### Pancrelipase:

Species : Rabbit  
Method : OECD Test Guideline 404  
Result : Skin irritation  
Remarks : Based on data from similar materials

#### Serious eye damage/eye irritation

Causes serious eye irritation.

#### Components:

##### Pancrelipase:

Result : Irritation to eyes, reversing within 21 days  
Remarks : Based on data from similar materials

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

#### Components:

##### Pancrelipase:

|                 |   |  |
|-----------------|---|--|
| Exposure routes | : | Inhalation                             |
| Species         | : | Humans                                 |
| Result          | : | positive                               |
| Remarks         | : | Based on data from similar materials   |
| Assessment      | : | May cause sensitisation by inhalation. |

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Pancrelipase:

|                       |   |   |
|-----------------------|---|---|
| Genotoxicity in vitro | : | Test Type: Bacterial reverse mutation assay (AMES)<br>Method: OECD Test Guideline 471<br>Result: negative<br>Remarks: Based on data from similar materials    |
|                       |   | Test Type: In vitro mammalian cell gene mutation test<br>Method: OECD Test Guideline 476<br>Result: negative<br>Remarks: Based on data from similar materials |
|                       |   | Test Type: Chromosome aberration test in vitro<br>Method: OECD Test Guideline 473<br>Result: negative<br>Remarks: Based on data from similar materials        |

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

Not classified based on available information.

#### Components:

##### Pancrelipase:

|                      |   |  |
|----------------------|---|--|
| Effects on fertility | : | Test Type: Two-generation reproduction toxicity study<br>Species: Rat<br>Application Route: Ingestion<br>Result: negative<br>Remarks: Based on data from similar materials |
|----------------------|---|--|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

##### **Pancrelipase:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 13 Weeks  
Method : OECD Test Guideline 408  
Remarks : Based on data from similar materials

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **Pancrelipase:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: Based on data from similar materials

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 10 - 100 mg/l

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

|                                  |  |
|----------------------------------|--|
| aquatic invertebrates            | Exposure time: 48 h<br>Method: OECD Test Guideline 202<br>Remarks: Based on data from similar materials  |
| Toxicity to algae/aquatic plants | : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 1 - 10 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201<br>Remarks: Based on data from similar materials<br><br>NOEC (Desmodesmus subspicatus (green algae)): > 1 mg/l<br>Exposure time: 72 h<br>Method: OECD Test Guideline 201<br>Remarks: Based on data from similar materials |

### 12.2 Persistence and degradability

#### Components:

#### **Pancrelipase:**

Biodegradability : Result: Readily biodegradable.

### 12.3 Bioaccumulative potential

#### Components:

#### **Pancrelipase:**

Partition coefficient: n-octanol/water : log Pow: < 4

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

### SECTION 13: Disposal considerations

#### 13.1 Waste treatment methods

- |                        |   |  |
|------------------------|---|--|
| Product                | : | Dispose of in accordance with local regulations.<br>According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.<br>Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.<br>Do not dispose of waste into sewer. |
| Contaminated packaging | : | Empty containers should be taken to an approved waste handling site for recycling or disposal.<br>If not otherwise specified: Dispose of as unused product.  |
- 

### SECTION 14: Transport information

#### 14.1 UN number or ID number

- |      |   |                                   |
|------|---|-----------------------------------|
| ADN  | : | Not regulated as a dangerous good |
| ADR  | : | Not regulated as a dangerous good |
| RID  | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA | : | Not regulated as a dangerous good |

#### 14.2 UN proper shipping name

- |      |   |                                   |
|------|---|-----------------------------------|
| ADN  | : | Not regulated as a dangerous good |
| ADR  | : | Not regulated as a dangerous good |
| RID  | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA | : | Not regulated as a dangerous good |

#### 14.3 Transport hazard class(es)

- |      |   |                                   |
|------|---|-----------------------------------|
| ADN  | : | Not regulated as a dangerous good |
| ADR  | : | Not regulated as a dangerous good |
| RID  | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |
| IATA | : | Not regulated as a dangerous good |

#### 14.4 Packing group

- |      |   |                                   |
|------|---|-----------------------------------|
| ADN  | : | Not regulated as a dangerous good |
| ADR  | : | Not regulated as a dangerous good |
| RID  | : | Not regulated as a dangerous good |
| IMDG | : | Not regulated as a dangerous good |

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

**IATA (Cargo)** : Not regulated as a dangerous good

**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation (Annex XIV) : Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

#### Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

---

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



ORGANON

## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H315 : Causes skin irritation.  
H319 : Causes serious eye irritation.  
H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled.

### Full text of other abbreviations

Eye Irrit. : Eye irritation  
Resp. Sens. : Respiratory sensitisation  
Skin Irrit. : Skin irritation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Pancrelipase Formulation

|         |                |               |                                 |
|---------|----------------|---------------|---------------------------------|
| Version | Revision Date: | SDS Number:   | Date of last issue: 30.09.2023  |
| 1.9     | 06.04.2024     | 5325641-00010 | Date of first issue: 22.11.2019 |

---

### Classification of the mixture:

|               |      |
|---------------|------|
| Skin Irrit. 2 | H315 |
| Eye Irrit. 2  | H319 |
| Resp. Sens. 1 | H334 |

### Classification procedure:

|                    |
|--------------------|
| Calculation method |
| Calculation method |
| Calculation method |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN